Qiagen N : 2025 Annual Report 2025 Annual Financial Report
QGEN
Published on 05/12/2026 at 04:58 am EDT
QIAGEN N.V.
Annual Report 2025
QIAGEN N.V. | Annual Report 2025 Overview Management Report Corporate Governance Financial Statements Appendices Page 1
Table of Contents
Overview
115
Consolidated Financial Statements
116
Report of Independent Registered Public Accounting Firm
121
Report of Independent Registered Public Accounting Firm
123
Report of Independent Registered Public Accounting Firm
124
Consolidated Balance Sheets
126
Consolidated Statements of Income
127
Consolidated Statements of Comprehensive Income
128
Consolidated Statements of Changes in Equity
129
Consolidated Statements of Cash Flows
131
Notes to Consolidated Financial Statements
208
Appendices
209
Articles of Association
221
Principal Accountant Fees and Services
222
Taxation
228
Government Regulations
241
Exchange Controls
242
Documents on Display
243
Controls and Procedures
245
Further Information
Strategy at a Glance
Key Figures
Sustainability
Executive Committee
15 Management Report
16 Business and Operating Environment
17 Strategy, Business Model and Value Chain
22 Operating Environment
35 Risks and Risk Management
54 Financial and Share Performance
54 Operating and Financial Review
68 QIAGEN Shares
72 Corporate Governance
73 Message from the Chair of the Supervisory Board
76 Governance Structure
78 Managing Board
80 Supervisory Board
86 Supervisory Board Report
97 Board-Related Matters
99 Shareholder Meetings and Share Capital
105 Additional Information
110 Compensation of Managing Board Members and Supervisory Directors
QIAGEN N.V. | Annual Report 2025 Overview Management Report Corporate Governance Financial Statements Appendices Page 2
Quick Links to Main Sections
Overview
Go to section
Management Report
Go to section
Corporate Governance
Go to section
Supervisory Board Report
Go to section
Financial Statements
Go to section
Appendices
Go to section
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 3
Overview
4 Our Strategy at a Glance
10 Key Figures
11 Sustainability at QIAGEN
16 Executive Committee
Overview
QIAGEN N.V. | Financial Report 2023 Management Report Corporate Governance Financial Statements Appendices Page 4
Overview
Growth pillars
QIAcuity digital PCR
QIAstat-Dx
QIAGEN Digital Insights (QDI)
Sample technologies
QuantiFERON
Our strategy at a glance
QIAGEN is a global leader in Sample to Insight solutions, helping customers transform biological samples into valuable molecular insights. In a rapidly evolving healthcare and life sciences landscape, we enable faster, more accurate answers across the continuum from research to clinical care.
Our strategy is focused on delivering solid profitable growth by sharpening our portfolio around attractive growth pillars where QIAGEN has established leadership positions, differentiated technologies and scalable market opportunities. These growth ambitions are supported by new product launches, focused commercial investments and continued expansion in high-growth applications across Life Sciences and molecular diagnostics.
QIAGEN aims for strong, profitable growth by streamlining its portfolio, improving operational efficiency, and digitizing processes. These efforts will free resources for innovation, commercial growth and long-term value creation.
QIAGEN is enhancing efficiency and profitability through portfolio streamlining, organizational simplification, process improvements and site optimization. Central to this strategy is digitization, using digital tools and AI to drive growth, productivity and better decision-making.
Achieving our strategy depends on the strength of QIAGEN's culture. We are focused on building a culture of empowerment, accountability and ownership, supported by a reinvigorated leadership team and clear strategic priorities.
QIAGEN remains committed to responsible business practices and its ESG goals, including a validated target to reach net zero carbon emissions by 2050 and continued contributions to public health partnerships around the world. By combining focused growth, operational discipline and responsible leadership, QIAGEN aims to create sustainable long-term value for customers, patients, employees, shareholders and society.
Overview
QIAGEN N.V. | Financial Report 2023 Management Report Corporate Governance Financial Statements Appendices Page 5
Overview
Digital PCR for research and clinical
QIAcuity digital PCR
QIAcuity is QIAGEN's digital PCR platform designed to deliver highly precise and sensitive nucleic acid detection and quantification. Its nanoplate-based technology enables reliable analysis of complex samples and supports a broad range of applications in research, biopharma and clinical healthcare.
Key features
>3,200
cumulative placements since launch
>270,000
QIAcuity dPCR assays on GeneGlobe
>800
publications referencing QIAcuity dPCR (2025)
Key achievements
Low- to high-throughput capabilities
Fully integrated walkaway automation
Faster and lower cost than NGS1
More accurate than qPCR2
Delivered in ~2 hours compared to droplet digital PCR
1 NGS - Next-generation sequencing
2 qPCR - Quantitative PCR
Overview
QIAGEN N.V. | Financial Report 2023 Management Report Corporate Governance Financial Statements Appendices Page 6
Overview
Syndromic testing for rapid clinical results
QIAstat-Dx
QIAstat-Dx is QIAGEN's syndromic testing platform, enabling rapid detection of multiple pathogens from a single patient sample. The system is designed to support timely clinical decision-making by delivering actionable results across a range of infectious disease syndromes.
Key features
>5,200
cumulative placements since launch
>70%
of customers use
≥ 3 panel types
~100
countries with QIAstat-Dx customers
Key achievements
Panels designed to help clinicians take action
Low- to high-throughput capabilities
Unique direct access to Ct values, adding insights when multiple pathogens are detected
Overview
QIAGEN N.V. | Financial Report 2023 Management Report Corporate Governance Financial Statements Appendices Page 7
Overview
Bioinformatics to create genomic data insights
QIAGEN Digital Insights (QDI)
QIAGEN Digital Insights provides advanced bioinformatics solutions that help researchers and clinicians analyze, interpret and act on complex biological data. By combining human-curated knowledge bases with artificial intelligence and advanced analytics, QDI supports applications in disease research, drug development and precision medicine.
Key features
>100,000
citations in literature
>25 years
of experience amassing the largest knowledge base in the world
>5.5 million
NGS1 patient test cases analyzed and interpreted
Key achievements
Robust portfolio of bioinformatic software for single-cell, multiomics and biological analysis and interpretation, including Ingenuity Pathway Analysis (IPA) and CLC Genomics.
Software for clinical testing Clinical and IVDR2-compliant software for secondary and tertiary analysis of NGS data across oncology and hereditary testing, including QCI3 Interpret and Franklin by QIAGEN.
1 NGS - Next-generation sequencing
2 IVDR - In vitro diagnostic regulation
3 QCI - QIAGEN Clinical Insights
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 8
DNA/RNA isolation and automation
Sample technologies
Sample technologies remain the foundation of QIAGEN's Sample to Insight portfolio. High-quality sample collection, stabilization, DNA and RNA purification and automated sample preparation are essential to generating reliable downstream results across research and clinical workflows.
Key features
>80%
of labs worldwide use QIAGEN Sample tech solutions1
>50,000
mentions in publications annually
>120 million
preparations sold to customers worldwide
Key achievements
1 2024 QIAGEN customer survey
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 9
Leading blood-based technology for TB infection
QuantiFERON
QuantiFERON-TB Gold Plus is a leading blood-based test for the detection of tuberculosis infection and an important contributor to global public health efforts to control and eliminate TB. The test offers greater specificity than the traditional tuberculin skin test by avoiding false positives linked to prior BCG vaccination.
Key features
>2,700
publications underscoring clinical value
>130
countries with QuantiFERON customers
>120
patents in 34 countries beyond 2030
Key achievements
> 97% specificity and > 94% sensitivity with unique CD4 / CD8 T-cell technology
Manual to fully automated solutions and only a single patient visit required
LIMS connectivity for streamlined data handling
Trusted worldwide Endorsed by WHO1, U.S. CDC2 and IPPA3
1 WHO - World Health Organization
2 U.S. CDC ‒ U. S. Centers for Disease Control and Prevention
3 IPPA ‒ International Panel on Progress Against TB
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 10
Key Figures
A global company with scale
$2.1 billion
2025 sales
Subsidiaries
35
subsidiaries in more than 25 countries
Geographic regions
14%
52%
Customers
>500,000
customers worldwide
Product type
34%
90%
10%
Americas EMEA
Asia-Pacific
and rest of world
Instruments
Consumables and related products
Portfolio
>500
core products comprising of kits, instruments and bioinformatics
Employees
~5,700
employees representing 75 nationalities
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 11
Sustainability at QIAGEN
2025 highlights
Environmental
4%
reduction in Scope 1 and 2 emissions compared to 2024
Social
10
local employer of choice awards
Governance
QIAintegrity line
enabled for reporting ethical concerns
Advancing sustainability as a strategic commitment
At QIAGEN, sustainability is central to how we advance science and improve healthcare. As a global Sample to Insight leader, we see environmental and social responsibility as essential to long-term value creation and sustainable growth.
Our strategy is embedded in our corporate framework, supporting responsible innovation and operational excellence across all functions. We engage regularly with stakeholders, including customers, employees, regulators, suppliers and shareholders, to ensure our approach reflects evolving expectations and regulatory requirements.
In line with the Corporate Sustainability Reporting Directive (CSRD), we continue to advance our ESG framework with clear targets, measurable actions and transparent reporting.
Our priorities include reducing plastic usage and advancing more sustainable product design, lowering greenhouse gas emissions across our operations and value chain, and strengthening collaboration with suppliers to promote environmental and social responsibility.
As part of our CSRD reporting, we obtained a limited assurance opinion on our Sustainability Statement, reinforcing the transparency and credibility of our disclosures. The full statement is publicly available on the QIAGEN website, detailing our performance, progress and long-term commitments.
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 12
Executive Committee
Thierry Bernard
Chief Executive Officer and Managing Director
Roland Sackers
Chief Financial Officer and Managing Director
Fernando Beils
Senior Vice President,
Head of Global Commercial Operations
Stephany Foster
Senior Vice President, Head of Human Resources
Antonio Santos
Senior Vice President, Head of Global Operations
Nitin Sood
Senior Vice President, Head of Product Portfolio & Innovation
Jean-Pascal Viola
Senior Vice President, Head of Corporate Strategy & Business Development
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 13
Members of the Executive Committee for the year ended December 31, 2025:
Thierry Bernard (born 1964; U.S./French) joined QIAGEN in February 2015 to lead our growing presence in molecular diagnostics, which involves the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis and became a member of the Managing Board in 2021. Before joining QIAGEN, Mr. Bernard spent 15 years at bioMérieux SA in roles of increasing responsibility, most recently serving as Corporate Vice President for Global Commercial Operations, Investor Relations and the Greater China Region. Earlier in his career, he held senior management positions at several other leading international companies. He is also a member of the Board of Directors of Neogen Corporation and Bruker Corporation, and previously served as Chair of the AdvaMedDx Board of Directors, a U.S. industry trade association. Mr. Bernard has earned degrees and certifications from Sciences Po, LSE, the College of Europe, Harvard Business School, Centro de Comercio Exterior de Barcelona and has been appointed Conseiller du Commerce Extérieur by the French government.
Mr. Bernard will step down as CEO after the appointment of a successor which is planned to occur in 2026.
Roland Sackers (born 1968; German) joined QIAGEN in 1999 as Vice President Finance and has been Chief Financial Officer since 2004. In 2006, Mr. Sackers became a member of the Managing Board. From 1995 to 1999, he was an auditor at Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft. Since 2019, Mr. Sackers has served on the Supervisory Board of Evotec SE, a publicly listed company based in Germany, becoming Chair of the Audit Committee in 2019 and Vice Chair of the Supervisory Board in 2021. He is also Chair of the Board of the German industry association BIO Deutschland. Mr. Sackers earned his Diplom-Kaufmann from the University of Münster.
Fernando Beils (born 1972; U.S./German) joined QIAGEN in 2023 as Senior Vice President, Head of the molecular diagnostics Business Area, and member of the Executive Committee, and was named Head of Global
Commercial Operations in January 2025. He has worked in various global leadership roles within the diagnostics industry during his career, and most recently served as Vice President and General Manager of the Genetic Testing Solutions Business at Thermo Fisher Scientific. Prior to this role, he spent over two decades at Siemens in commercial, strategy and finance roles, and in his last role as Global Head of the molecular diagnostics Business Unit at Siemens Healthineers. He earned a degree in Business Administration from EWA Madrid and the University Mosbach School of Business.
Stephany Foster (born 1978; U.S.) joined QIAGEN in 2005 as Head of Global Internal Audit and has been in her current position as Senior Vice President, Head of Global Human Resources and member of the Executive Committee, since 2019. Prior to this position, Ms. Foster served as Vice President, Head of Compensation and Benefits, and earlier as Vice President, Head of Internal Audit. Prior to joining QIAGEN, she worked in internal audit at Morgan Franklin, Independence Air and PricewaterhouseCoopers.
Ms. Foster holds both a Bachelor's and Master's degree in Accounting from the University of Notre Dame.
Antonio Santos (born 1968; U.S./Portuguese) joined QIAGEN in April 2022 as Senior Vice President, Global Operations, and a member of the Executive Committee. Mr. Santos has more than 25 years of experience in manufacturing diagnostics and medical devices. Prior to joining QIAGEN, he was Senior Vice President, Americas Operations & Global Third Party Products, at bioMérieux in St. Louis, Missouri, where he oversaw since 2013 all manufacturing and supply operations in the Americas. He has worked in international roles in China, Europe and the U.S., and previously served as Vice President Operations at Reliable Biopharmaceutical in the U.S. and at Hovione Pharmasciencia in Portugal, China and the U.S. After studying chemical engineering at the Nova University of Lisbon, School of Science and Technology, he earned an MBA at Rutgers University.
Nitin Sood (born 1972; U.S.) joined QIAGEN in 2023 as Senior Vice President, Head of the Life Sciences Business Area, and member of the Executive Committee, and was named Head of Product Portfolio & Innovation in January 2025. He most recently served as Chief Commercial Officer, MRD, at
Overview
QIAGEN N.V. | Annual Report 2025 Management Report Corporate Governance Financial Statements Appendices Page 14
Adaptive Biotechnologies. He has enjoyed a 20-year career in the diagnostic and Life Science fields, having also held leadership roles at Guardant Health, PerkinElmer, Agilent Technologies and NuGEN Technologies. He holds a Master's degree from Delhi University in Molecular Biology and a Master's degree from Ball State University in Computer Science.
Jean-Pascal Viola (born 1975; Canadian) joined QIAGEN in 2005 as part of the acquisition of Nextal Biotechnologies Inc., a provider of technologies for protein crystallization where he served as President and CEO. He has served since 2023 as Senior Vice President, Corporate Strategy and Business Development. Prior to that, he served since 2020 as Senior Vice President, Head of molecular diagnostics Business Area, which involves QIAGEN's activities supporting customers in clinical healthcare. He has been a member of the Executive Committee since 2019. He earned a Bachelor's degree in Biochemistry from the University of Montreal, Canada.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 15
Management Report
16 Business and Operating Environment
17 Strategy, Business Model and Value Chain
22 Operating Environment
35 Risks and Risk Management
54 Financial and Share Performance
54 Operating and Financial Review
68 QIAGEN Shares
72 Corporate Governance
73 Message from the Chair
76 Governance Structure
78 Managing Board
80 Supervisory Board
86 Supervisory Board Report
97 Board-Related Matters
99 Shareholder Meetings and Share Capital
105 Additional Information
110 Compensation of the Managing Board Members and Supervisory Directors
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 16
Business and Operating Environment
QIAGEN is a leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. We serve over 500,000 customers globally in Life Sciences (academia, pharma research and development, industrial applications, primarily forensics) and molecular diagnostics for clinical healthcare. As of December 31, 2025, we employed approximately 5,700 people in over 35 locations worldwide.
QIAGEN was founded in 1984 and began operations in 1986 as a pioneer in the emerging biotechnology sector with a revolutionary method that standardized and accelerated the extraction and purification of nucleic acids from biological samples, which means any material containing DNA, RNA or proteins. As molecular biology and genomic knowledge has grown to influence many areas of daily life, we have expanded to serve the full spectrum of market needs while developing new instruments, consumables and digital solutions, partnering with researchers and pharmaceutical companies, and acquiring companies and technologies that best complement our portfolio. We continue to accelerate our portfolio growth and increase our efficiency and effectiveness while also enhancing our customer experience, our corporate citizenship and our position as an employer of choice.
Our growth has been funded through internally generated funds as well as through debt offerings in recent years.
Our Global Shares are listed on the New York Stock Exchange under the ticker symbol QGEN and on the Frankfurt Stock Exchange as QIA.
QIAGEN N.V. is the holding company for more than 60 consolidated subsidiaries, many of which have the primary function of distributing our products and services on a regional basis. Certain subsidiaries also have
research and development or production activities. The Company is registered under its commercial and legal name QIAGEN N.V. with the trade register (kamer van koophandel) of the Dutch region Limburg Noord under file number 12036979. QIAGEN N.V. is incorporated under Dutch law as a public limited liability company (naamloze vennootschap) and is organized as a holding company. Our principal executive office is located at Hulsterweg 82, 5912 PL Venlo, The Netherlands, and our telephone number is +31-77-355-6600.
Further information on QIAGEN can be found at https://www.qiagen.com. The
U.S. Securities and Exchange Commission (SEC) website at https://www.sec.gov contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Information contained in, or that can be accessed through, our website is not a part of, and shall not be incorporated by reference into, this Annual Report. We have included our website address in this document solely as an inactive textual reference. We file our IFRS annual report (in accordance with EU-IFRS and Dutch law) with the AFM, including the register that the AFM maintains.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 17
Strategy, Business Model and Value Chain
QIAGEN provides sample and assay technologies that enable customers to extract, detect and interpret molecular information from biological samples. From decoding DNA to accelerating life-saving breakthroughs, our vision is simple: to make improvements in life possible. We create value by offering integrated workflows that combine consumables with instruments, automation and bioinformatics. This approach allows customers to standardize research and molecular testing and generate actionable insights across applications faster, better and more efficiently.
Our strategy is anchored by a commitment to deliver solid profitable growth by focusing our resources on a group of pillars that represented $1.5 billion in sales, approximately 72% of sales, in 2025 and that are expected to reach combined annual sales of approximately $2 billion by 2028. We are aligning our investments within these pillars to maximize sales in proven high-growth markets.
The pillars involve three product groups where QIAGEN is developing leadership positions: the digital PCR (Polymerase Chain Reaction) platform QIAcuity, the clinical PCR syndromic testing solution QIAstat-Dx and the QIAGEN Digital Insights portfolio of bioinformatics solutions for improved analysis and interpretation of complex genomic data. Additionally, two pillars involve product groups where QIAGEN has strong top positions and where we want to consolidate our leadership: Sample technologies that are used to gain access to DNA and RNA from a biological sample and the QuantiFERON technology platform for latent disease detection, best known for its use in detecting latent tuberculosis (TB).
We classify our products into two main categories: consumables and related revenues; and instruments and related services. Global Presence by Product Category and Geographic Market and QIAGEN Product Groups provide additional details
We manufacture our products at facilities in the United States, Europe and China. In China, products are primarily made for the local market. For more
information about our manufacturing sites, please refer to the Description of Property section.
Our commercial teams are organized into specialized groups across three major regions: Americas; Europe, Middle East and Africa (EMEA); and Asia Pacific and Japan (including China). In certain markets, we also work with third-party distributors to extend our reach. For more information, please refer to the Sales and Marketing section. Details about our employees can be found in the Employees section.
QIAGEN operates a centralized distribution network with regional hubs responsible for local logistics.
Building a sustainable business
Our products support scientific progress and healthcare by enabling molecular insights that can contribute to improved decision-making and patient outcomes worldwide. We are committed to sustainable business practices integrating stakeholder perspectives-including those of customers, employees, regulators and public authorities, suppliers and shareholders-into relevant aspects of our operations.
Our sustainability policy outlines key principles and responsibilities for QIAGEN employees regarding environmental, social and governance (ESG) matters, reflecting our commitment to a more sustainable future. Oversight of sustainability is provided by the Supervisory Board, through its Nomination & Governance Committee. The Managing Board is responsible for integrating sustainability into strategy, and works with the Executive Committee on operational execution.
Our targets and actions address priorities such as reducing the use of plastic and advancing environment-friendly product solutions; lowering emissions across our operations and supply chain; and working with suppliers to promote environmental and social responsibility. Through these initiatives, we aim to embed sustainability considerations across our business activities and product life cycle.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 18
Global presence
Delivering products to
>160 countries
Direct sales in
>40 countries
Global presence
Value is created across QIAGEN's value chain through innovation in sample and assay technologies, high-quality manufacturing and regulatory-compliant supply. As part of its business model, QIAGEN integrates post-market surveillance into the life-cycle management of its products. The ongoing monitoring of product performance supports the early identification of
quality-related risks, underpins regulatory compliance across markets, and helps maintain trust in QIAGEN's solutions among customers, patients and end users. These efforts are supported by commercial execution and global distribution capabilities. Our research and development are carried out within manufacturing entities and specialized R&D centers. Manufacturing sites source raw materials and semi-finished products from affiliated entities and independent third parties to support the production of QIAGEN consumables, instruments and related solutions. Sales to end customers are managed through local sales subsidiaries and, in certain markets, third-party distributors. A centralized distribution network connects manufacturing entities with local sales organizations, supported by two global distribution hubs that consolidate demand and optimize supply logistics.
Our products serve more than 500,000 customers across the continuum from Life Sciences (academia, pharmaceutical R&D and applied testing) to molecular diagnostics (clinical healthcare). QIAGEN operates globally, with significant markets in the Americas, Europe, Middle East, Africa (EMEA), Asia Pacific and Japan (including China).
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 19
Upstream
Our
Downstream
operations Sales to >500,000 customers
Raw materials
R&D services and in-licensing Finished goods
Logistical and warehousing services Semi-finished goods
IT and other services
~5,700 QIAGENers across all EC functions Manufacturing in EMEA, Americas and APAC regions
Research and Development
Consumables Instruments Bioinformatics
(digital insights)
Consumables Instrumentation services Instruments
Licensing (e.g., patents) Bioinformatics
Material topics
Climate change • Climate change • Consumers and end users • Climate change
Resource use and circular economy (e.g. resource inflows)
Business conduct
Resource use and circular economy (e.g., closing the loop, waste management)
Own workforce
Working conditions
Diversity and inclusion
Resource use and circular economy (e.g. products, services, waste)
Business conduct
Workers in the value chain • Business conduct
Occupational health and safety
Workers in the value chain
Consumers and end-users
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 20
Understanding and addressing the interests and expectations of our stakeholders is essential for our business strategy and long-term value creation. In 2025, we actively engaged with stakeholders through various channels, incorporating their insights into our materiality assessment, business processes and capital allocation dialogue. These engagements supported decisions on product portfolio priorities, operational improvements, transparency in external reporting and the way we communicate our approach to profitable growth, investment discipline and long-term shareholder value creation.
In particular, engagement with shareholders and the financial community provided feedback not only on sustainability performance and governance, but also on strategy execution, capital deployment priorities and the balance between investing for future growth and maintaining financial discipline. This dialogue helps us explain how we allocate resources to strategic growth pillars, innovation, operational capabilities and other value-enhancing initiatives, while maintaining a focus on returns, resilience and transparency. In accordance with the Dutch Corporate Governance Code, our Stakeholder Engagement Policy is available on our website.
Stakeholders How we engage Why we engage How we respond
Shareholders and the financial community
Quarterly reports and earnings calls, including strategy and capital allocation updates
Annual report and annual general meeting communications, including long-term value creation priorities
Regular roadshows and investor calls on growth, portfolio priorities and returns
Investor relations website and related shareholder communications
Investor feedback
Long-term shareholder value creation
Capital deployment to investment priorities with highest returns
Financial resilience
Understanding investor expectations toward sustainability
Business conduct: attracting responsible investors
Clearer communication on long-term shareholder value creation
Communication and execution of capital allocation priorities, including strategic acquisitions, digital capabilities and growth pillar investments
Communication of shareholder return actions, including the annual cash dividend and synthetic share repurchase programs
Stronger linkage between strategy, resource allocation and profitable growth
Increased transparency on sustainability performance
ESG information embedded in internal and external communications
Expanded CDP environmental reporting
Employees • Strategic meetings: annual kick-offs and quarterly
feedback checks
Reviews: one-on-one sessions and 180° feedback
Engagement: surveys, pulse checks, events and webinars
Trainings: management and regulatory sessions, ESG awareness
Foster performance culture
Ensure highest health and safety
Equal treatment and opportunities for all
Employee development, training and skills
Annual employee survey results show QIAGEN as having a high-performance culture
Recognition of QIAGEN as top employer in several regions
Local site action plans to enhance workplace culture
Increased safety awareness
Reduction in unstaffed positions
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 21
Stakeholders How we engage Why we engage How we respond
Customers • Surveys: customer satisfaction measurement
Digital tools: web chat and 24/7 service portal
Events: conferences, trade fairs, roadshows and infotainment shows; best practice sharing at our facilities
Engagement: bilateral meetings, production tours, training, customer audits
Sustainability: questionnaires and dedicated webpage
Suppliers • Workshops on target costing design
Risk assessment, strategic reviews, supplier days
Best practice workshops, bilateral engagement, joint initiatives, webinars with employees
Strong ongoing customer engagement and retention
Ensure timely access to products and services
Support sustainable lab practices and efficient waste management
Supply chain security and risk reduction
Business conduct: responsible sourcing standards
Sustainability commitments
Incorporation of customer requirements into product and service offering
Expansion of product portfolio with increasing focus on sustainable products and plastics reduction
Service improvements, e.g., web chat functionalities and Net Promoter Score (NPS) above internal benchmarks
Lab waste treatment pilot
Cost stability in challenging macroeconomic environment
Mapped strategic supplier base to reduce supply risk and assess sustainability factors
Pilot projects on low-carbon solutions
General society and local communities
Banks and financial institutions
Collaboration with public health laboratories, research and academic institutions around the world
Mandatory reporting and information (e.g., annual report, non-financial reporting)
Bilateral meetings
Access to products and services: enhancement of access to healthcare
Efficient financing costs
Improvements in ESG ratings
Laboratory infrastructure and capacity building to support pandemic preparedness
Response initiatives, local surveillance
Development of new tools for pathogen detection
Reduced financing costs for debt offerings
Favorable ESG performance-linked loan conditions
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 22
Operating Environment
In 2025, global economic growth remained moderate, with the International Monetary Fund (IMF) estimating real GDP growth of about 3%. Inflation eased in many economies, supporting the start of monetary policy easing in some markets, although underlying price pressures persisted in parts of the advanced economies. Growth remained uneven, with advanced economies expanding by around 1.5% and emerging market and developing economies growing at just above 4%.
Economic activity continued to be influenced by elevated public and private debt levels, trade policy uncertainty and geopolitical tensions, contributing to a cautious operating environment across many sectors.
The Life Sciences and molecular diagnostics industries showed mixed conditions in 2025. While demand growth continued in several application areas-including oncology, infectious disease testing and biopharmaceutical research
-customer purchasing patterns remained uneven across regions. Companies increasingly emphasized expanding the use of installed instrument platforms and menu breadth to drive growth in clinical and research settings.
QIAGEN remained positioned to address these trends through its global footprint and commercial scale, supported by key platforms such as QIAstat-Dx,
for which cumulative placements exceeded 5,200 instruments worldwide at year-end 2025.
The addressable Life Sciences and molecular diagnostics segments are estimated at about $12 billion in annual sales, with expectations for continued single-digit growth.
Our leadership in molecular research and testing solutions leverages our product portfolio across a wide range of applications. These are grouped into two main categories:
Consumables and related revenues, which include consumables kits, bioinformatics solutions, royalties, co-development milestone payments and services (90% of total net sales in 2025)
Instruments and related services and contracts (10% of total net sales in 2025)
Sample technologies represent one of our pillars and include products involved in the first step of any molecular lab process.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 23
Input demands
Processing
Target analytes
Tissue
Low / high-volume
Manual
Genomic DNA
Cells
Saliva
Low-quantity
Plasmid DNA
DNA
Sequencing
Input demands
Low-quantity
Automated
mRNA, rRNA
High-quantity
Low- to high-
miRNA
Tubes / plates
throughput systems
Circulating tumor cells and proteins
Selected biological samples
Applications
Blood
Serum Plasma Urine
Other body
fluids Bone Plants
Soil
Tubes / plates
cfDNA
amplification
Arrays
Gene editing Epigenetics
Cellular analytics
/ NGS
Liquid biopsy Microbiome Gene silencing Proteomics
Our broad portfolio of Sample technologies includes consumables and instruments used in sample collection, stabilization, storage, purification and quality control. Some of our consumables are designed to run on our instruments, while others are universal kits designed for use with any molecular-testing platform. These products are used in research and applied testing (forensics/human identification and food safety) in laboratories as well as clinical testing.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 24
Sample technologies Selected QIAGEN brands
Primary Sample technology consumables
Secondary Sample technology consumables
Sample technology instruments
Diagnostic solutions
Diagnostic solutions include our molecular testing platforms and consumables,
covering two of our pillars with QuantiFERON and QIAstat-Dx. They also
include Precision Diagnostics, which comprises companion diagnostic co-
development revenues from projects with pharmaceutical companies, regulated
assays and solutions for laboratory-developed tests. Additional areas include
oncology and sexual and reproductive health for detection of various diseases
and for other laboratory processes.
Nucleic acid stabilization and purification kits designed for primary sample materials (DNA, RNA), manual and automated processing for genotyping, gene expression, viral and bacterial analysis
Mainly based on silica membrane and magnetic bead technologies
QIAamp
PAXgene
AllPrep
DNeasy
QIAprep&
RNeasy
MagAttract
QIAwave
Kits and components for purification of nucleic acids from secondary sample materials (e.g., gel, plasmid DNA)
QIAprep
QIAGEN Plasmid
HiSpeed
QIAquick
QIAfilter
EndoFree
DyeEx
Instruments for nucleic acid purification, quality control and accessories
QIAsymphony
EZ2 Connect
TissueLyser III
QIAcube Connect
EZ2 Connect MDx
QIAcube HT
QIAxcel Connect
QIAcube Connect MDx
QIAsprint Connect
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 25
Diagnostic solutions Selected QIAGEN brands
Immune response consumables
Oncology and sexual and reproductive health consumables
Sample to Insight instruments and dedicated assays
PCR/Nucleic acid amplification
PCR/Nucleic acid amplification involves our research and applied PCR
solutions and components. The product group includes another of our pillars,
QIAcuity. We offer optimized solutions for end-point PCR, quantitative PCR and
digital PCR. Our kits, assays, instruments and accessories amplify and detect
targets and streamline workflow for virtually any application.
Interferon-Gamma Release Assay (IGRA) for latent TB testing
Assays for post-transplant testing, viral load monitoring
QuantiFERON
Assays for analysis of genomic variants such as mutations, insertions, deletions and fusions
Assays for prenatal testing and detection of sexually transmitted diseases and HPV
therascreen
AmniSure / PartoSure
ipsogen
digene HC2
One-step molecular analysis of hard-to-diagnose syndromes
Fully integrated PCR testing
QIAstat-Dx
QIAstat-Dx Rise
PCR/Nucleic acid amplification Selected QIAGEN brands
Research PCR consumables
Different generations of PCR, quantitative and digital PCR, reverse transcription and combinations (RT-PCR) kits for analysis of gene expression, genotyping and gene regulation, running on QIAGEN or third-party instruments and technologies
Human ID/Forensics assay consumables
QuantiTect
OneStep RT-PCR
OmniScript
QIAcuity
QIAGEN Multiplex
miRCURY
AllTaq
GeneGlobe
QuantiNova
HotStarTaq
UltraRun Long Range
Short tandem repeat (STR) assays for human ID, additional assays for food contamination • Investigator (human
ID / forensics)
PCR instruments
Digital PCR solutions
qPCR solutions OEM consumables
QIAcuity
Rotor-Gene Q
QIAgility • QIAcuityDx
Custom-developed and configured enzymes and PCR solutions that are sold to OEM customers • Provided on an individualized contract basis
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 26
Genomics/NGS
This product group includes our universal next-generation sequencing (NGS) solutions for use with any NGS sequencer as well as the full bioinformatics portfolio offered by QIAGEN Digital Insights, which also represents one of our pillars.
Genomics/NGS Selected QIAGEN brands
Universal NGS consumables
Predefined and custom NGS gene panels (DNA, RNA), library prep kits and components, whole genome amplification, DNA methylation analysis, etc.
Sequence-based assays for forensic genetic genealogy QIAGEN Digital Insights solutions
Bioinformatics solutions analyze and interpret data to deliver actionable insights from NGS. This includes freestanding software or cloud-based solutions and is integrated into many QIAGEN consumables and instruments.
QIAseq
GeneGlobe
QCI Secondary Analysis
QCI Interpret
QCI Precision
REPLI-g
EpiTect
CLC Workbenches
OmicSoft Lands
Ingenuity Pathway Analysis
ForenSeq Kintelligence
Biomedical Knowledge Base
HGMD
HSMD
PGXI
Other
Revenues from various sources, including protein biology products, royalties, intellectual property and freight charges.
We sell our products to more than 500,000 customers in two broad customer groups: molecular diagnostics (clinical testing) and Life Sciences (academia, pharmaceutical research and development and applied testing).
At the end of 2025, our current total addressable market was estimated at approximately $12 billion annually, with estimates indicating that this market opportunity would grow about 4-6% annually through 2028.
Molecular diagnostics
The molecular diagnostics market includes healthcare providers engaged in many aspects of patient care that require accurate diagnoses and insights to guide treatment decisions in oncology, infectious diseases and immune monitoring.
We offer one of the broadest portfolios of molecular technologies for healthcare. The success of molecular testing in healthcare depends on the ability to accurately analyze purified nucleic acid samples from sources such as blood, tissue, body fluids and stool. Automated systems process tests reliably and efficiently, often handling hundreds of samples simultaneously. Our range of assays for diseases and biomarkers speeds up and simplifies laboratory workflow and standardizes lab procedures.
Molecular testing is the most dynamic segment of the global in vitro diagnostics market. The pandemic has demonstrated the value of molecular testing in healthcare, and we expect the market to provide significant growth opportunities.
We have built a position as a preferred partner to co-develop companion diagnostics paired with targeted drugs and have created a rich pipeline of molecular tests that are transforming the treatment of cancer and other diseases. We have more than 30 master collaboration agreements with pharmaceutical industry customers, some with multiple co-development projects. Companion
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 27
diagnostics move through clinical trials and regulatory approvals, along with the paired drugs, to commercialization and marketing to healthcare providers.
Sample technologies Assay technologies Instruments Bioinformatics
For extraction from:
Tissue
Blood
Swabs, other
Indication areas
Oncology
Immune modulation
Infectious diseases Technologies: QuantiFERON, Polymerase Chain Reaction (PCR), Next-generation sequencing (NGS)
QIAstat-Dx
QIAsymphony RGQ
QIAcube Connect MDx
EZ2 Connect MDx
QIAstat Rise
QIAGEN Clinical Insight (QCI)
Hereditary diseases
Somatic and germline cancers
Other diseases
Life Sciences
The Life Sciences market includes governments and biotechnology companies, where researchers and scientists are using molecular testing technologies to advance scientific knowledge in the pursuit of new breakthroughs that can lead to new medicines and diagnostics for use in clinical healthcare. This market also includes the use of molecular testing technologies for applied applications, in particular for forensics as well as food and veterinary testing. These customers are all often served by public funding and research and development budgets within pharmaceutical companies.
We partner with customers across diverse disciplines in academia and industry, providing sample technologies, assay technologies, bioinformatics and services to universities and institutes, pharmaceutical and biotech companies, governments and law enforcement agencies.
We provide Sample to Insight solutions to academic and research institutions around the world. We focus on enabling researchers to use high-quality technologies to generate reliable, fast, highly reproducible results, sometimes replacing time-consuming traditional or in-house methods. We often partner with leading institutions on research projects and develop customized solutions such as NGS panels for the sequencing of multiple gene targets.
We are a global leader in solutions for governments and industry, particularly in forensic testing and human identification. The value of genetic "fingerprinting" has been proven in criminal investigations and examinations of paternity or ancestry, as well as in food safety. We provide sample collection and analytical solutions for law enforcement and human identification labs as well as advanced technologies for studies of microbiomes and their effect on health and the environment.
We have deep relationships with pharmaceutical and biotechnology companies. Drug discovery and development as well as translational research efforts increasingly employ genomic information, both to guide research in diseases and to differentiate patient populations that are most likely to respond to particular therapies. We estimate that about half of our sales to these companies supports research, while the other half supports clinical development, including stratification of patient populations based on genetic information. Also, QIAGEN Digital Insights solutions are widely used to guide pharmaceutical research and treatment options.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 28
Sample technologies Assay technologies Instruments Bioinformatics
~300 different kit types for extraction and purification of DNA, RNA and proteins from tissue, blood, cells, stool, plants, soil and other sample types
Real-time PCR
Digital PCR
Next-generation sequencing
QIAsymphony
QIAcube Connect
QIAcuity digital PCR
Ingenuity Pathway Analysis (IPA)
Genomics Workbench/Server
Microbial Pro Suite/RNA-seq
Microbial Epigenetics
The markets for most of our products are very competitive. Competitors may have developed, or could develop in the future, new technologies that compete with our products or even render our products obsolete. In sample technology products, we experience competition in various markets from other companies providing sample preparation products in kit form and assay solutions. These competitors include, but are not limited to, companies with a focus on nucleic acid separation and purification kits, assay solutions, reagents and instrumentation. We compete with other suppliers through innovative technologies and products, offering a comprehensive solution for nucleic acid collection, pre-treatment, separation and purification needs as well as downstream applications. Our products provide significant advantages in terms of speed, reliability, accuracy, convenience, reproducibility and ease of use.
Some of our other products within our molecular diagnostics customer class, such as tests for chlamydia, gonorrhea, hepatitis B virus, herpes simplex virus and CMV (cytomegalovirus), compete against existing screening, monitoring and diagnostic technologies, including tissue culture and antigen-based diagnostic methodologies. We believe the primary competitive factors in the market for gene-based probe diagnostics and other screening devices are clinical validation, performance and reliability, ease of use, time to result, standardization, cost, proprietary position, competitors' market shares, access to distribution channels, regulatory approvals and reimbursement.
We believe our competitors typically do not have the same comprehensive approach to sample-to-insight solutions as we do, nor do they have the ability to provide the broad range of technologies and depth of products and services that we offer.
Current and potential competitors may be in the process of seeking Federal Drug Administration (FDA) or foreign regulatory approvals for their respective products. Our continued future success will depend in large part on our ability to maintain our technological advantage over competing products, expand our market presence and preserve customer loyalty. There can be no assurance that we will be able to compete effectively in the future or that development by others will not render our technologies or products noncompetitive.
Net sales for the product categories are based on those revenues related to sample and assay products and related revenues, including bioinformatics solutions, as well as revenues derived from instrumentation sales.
Net sales (in millions) 2025 2024 2023
Consumables and related revenues
$1,876.4
$1,760.2
218.0
$1,726.2
Instrumentation
213.6
239.1
Total
$2,090.0
$1,978.2 $1,965.3
Geographical information
We sell our products in more than 160 countries. The following table shows total revenue by geographic market for the past three years (with net sales attributed to countries based on the location of the customer, as certain subsidiaries have international distribution):
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 29
Net sales (in millions) 2025 2024 2023
United States
$998.4
$942.0
89.6
$935.3
Other Americas
88.1
84.8
Total Americas
1,086.5
1,031.6 1,020.1
Europe, Middle East and Africa
712.8
648.5
298.2
624.6
Asia Pacific, Japan and Rest of World
290.7
320.7
Total
$2,090.0
$1,978.2 $1,965.3
Our business is not significantly impacted by seasonal factors. Historically, a portion of our sales has been to researchers, universities, government laboratories and private foundations whose funding is dependent upon grants from government agencies, such as the National Institutes of Health and similar bodies. To the extent that our customers experience increases, decreases or delays in funding arrangements and budget approvals, and to the extent that customers' activities are slowed, such as during times of higher unemployment, vacation periods or delays in approvals of government budgets or government shutdowns, we may experience fluctuations in sales volumes during the year or delays from one period to the next in the recognition of sales. Additionally, we have customers who are active in the diagnostics testing market, and sales to these customers fluctuate to the extent that their activities are impacted by public health concerns. For example, the timing and severity of viral infections such as influenza or the SARS-CoV-2 virus may impact demand for our products.
We are committed to expanding our global leadership in "Sample to Insight" solutions serving customers in the Life Sciences and clinical diagnostics. We target our research and development resources at the most promising technologies to address the unmet needs of our customers in healthcare and research labs in key geographic markets.
Innovation at QIAGEN follows parallel paths:
Creating new systems for automation of workflows - platforms for laboratories, hospitals and other users of novel molecular technologies
Expanding our broad portfolio of content - including assays to detect and measure biomarkers for disease or genetic identification
Integrating QIAGEN Digital Insights with the testing process - software and cloud-based resources to interpret and transform raw molecular data into useful insights
Innovation in automation systems positions us in the fast-growing fields of molecular testing and generates ongoing demand for our consumable products. We are developing and commercializing a robust pipeline of assays for preventive screening and diagnostic profiling of diseases, detection of biomarkers to guide Precision Diagnostics in cancer and other diseases and other molecular targets. Our assay development program aims to commercialize tests that will add value to our QIAsymphony and QIAstat-Dx automation systems in the coming years together with developing next-generation sequencing (NGS) kits to support our universal NGS franchise and our in vitro diagnostics partnership with Illumina. We continue to develop applications for the QIAcuity digital PCR system, which is designed to make digital PCR technology available to Life Sciences and clinical laboratories worldwide, as well as to other participants in the NGS market.
We market our products primarily through subsidiaries in markets with the greatest sales potential in the Americas, Europe, Australia and Asia.
Experienced marketing and sales staff, many of them scientists with academic degrees in molecular biology or related areas, sell our products and support our customers. Business managers oversee key accounts to ensure that we serve customers' commercial needs, such as procurement processes, financing, data on costs and the value of our systems, while maintaining collaborative relationships. In many markets, we have specialized independent distributors and importers.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 30
Our go-to marketing strategy focuses on providing differentiated, high-quality products across the value chain from Sample to Insight, integrating components into end-to-end solutions when possible and enhancing relationships with a commitment to technical excellence and customer service. Our omni-channel approach seeks to engage customers through their preferred channels -- online, by phone or in person - and to optimize investment in different customer types.
We continue to drive the growth of our digital marketing channels - including our website at https://www.qiagen.com, product-specific sites and social media. The recent pandemic saw an increase in virtual events and use of digital sales channels. We have likewise increased the activities in digital marketing to adapt to these market changes, such as installing an in-house studio to facilitate creation of video content and live virtual events.
Our eCommerce team works with clients to provide automated processes supporting a variety of electronic transactions and all major eProcurement systems.
My QIAGEN is an easy-to-use self-service portal that is personalized to our customers' needs and enables them to manage different activities in one central place. Customers can now easily reorder products, place bulk orders, apply quotes to their cart and track their order status. Functionality in the dashboard allows customers to monitor their instrument use and view the status of licenses and service agreements. Additionally, customers can access our exclusive content and services, such as webinars, handbooks and other documents.
Our GeneGlobe Design and Analysis Hub (https://www.geneglobe.com) is a valuable outreach to scientists in pharma and academia, enabling researchers to search and order from approximately 25 million pre-designed and custom PCR assay kits, NGS assay panels and other products. The hub brings next-level experiment planning, execution and follow-up to Life Science researchers, linking our QIAGEN Digital Insights solutions with ordering of assays to accelerate research.
We use a range of tools to provide customers with direct access to technical support, inform them of new product offerings and enhance our reputation for technical excellence, high-quality products and commitment to service. For
example, our technical service support allows existing or potential customers to discuss or ask questions about our products and molecular biology procedures with QIAGEN scientists online or by phone. Frequent communication with customers enables us to identify market needs, learn of new developments and opportunities, and respond with new products.
We also distribute publications, including our catalog, to current and potential customers worldwide, providing new product information, updates and articles about existing and new applications. In addition, we hold numerous scientific seminars at clinical, academic and industrial research institutes worldwide and at major scientific and clinical meetings. We conduct direct-marketing campaigns to announce new products and special promotions, and we offer electronic newsletters and webinars highlighting molecular biology applications.
For laboratories that frequently rely on our consumables, the QIAstock program maintains inventory on-site to keep up with their requirements. QIAGEN representatives make regular visits to replenish the stock and help with other needs, and we are automating this process with digital technologies. Easy-to-use digital ordering, inventory monitoring and customer-driven changes make QIAstock an efficient system for providing ready access to our products for the hundreds of customers worldwide who use this program.
We have made, and expect to continue making, investments in intellectual property. In 2025, additions to our intangible assets outside of business combinations totaled $6.1 million, and as of December 31, 2025, patent and license rights, totaled a net $38.6 million. While we do not depend solely on any individual patent or technology, we are significantly dependent in the aggregate on technology that we own or license. Therefore, we consider protection of proprietary technologies and products one of the major keys to our business success. We rely on a combination of patents, licenses and trademarks to establish and protect proprietary rights. As of December 31, 2025, we owned 280 issued patents in the United States, 214 issued patents in Germany and 1,569 issued patents in other major industrialized countries. We had 353 pending patent applications. Our policy is to file patent
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 31
applications in Western Europe, the United States and Japan. Patents in most countries have a term of 20 years from the date of filing the patent application. We intend to aggressively prosecute and enforce patents and to otherwise protect our proprietary technologies. We also rely on trade secrets, know-how, continuing technological innovation and licensing opportunities to develop and maintain our competitive position.
Our practice is to require employees, consultants, outside scientific collaborators, sponsored researchers and other advisers to execute confidentiality agreements at the start of their relationships with us. These agreements provide that all confidential information developed by or made known to the individual during the course of the relationship is to be kept confidential and not disclosed to third parties, subject to a right to publish certain information in scientific literature under specific circumstances and other exceptions. In the case of our employees, the agreements provide that all inventions conceived by individuals in the course of their employment will be our exclusive property, subject to local laws.
See Risk Factors included in Risks and Risk Management for details regarding risks related to our reliance on patents and proprietary rights.
We strive to ensure that our quality standards, compliance with laws and regulations as well as environmental and social standards are maintained along the entire value chain of suppliers and partners. We demand the same from our business partners. Suppliers are subjected to a risk analysis with regard to environmental and social criteria based on their geographic location. Our supplier policy, which all new suppliers sign, is available on our website and contains requirements with regard to legal compliance, bribery and corruption, labor rights, nondiscrimination and fair treatment, health and safety as well as environmental protection and conservation. In addition, first-tier suppliers must confirm REACH, RoHS and conflict minerals compliance, as appropriate. As part of our supplier assessment procedures, on a monthly basis, we evaluate the supply performance of our raw material and component suppliers. We assess, on a continuous basis, potential alternative sources of
such materials and components and, on a yearly basis, the risks and benefits of reliance on our existing suppliers.
We strive to maintain inventories at a sufficient level to ensure reasonable customer service levels and to guard against normal volatility in availability. We buy materials for our products from many suppliers and are not dependent on any one supplier or group of suppliers for our business as a whole. Raw materials generally include chemicals, raw separation media, biologics, plastics, electronics and packaging. Certain raw materials are produced under our specifications. We have inventory agreements with the majority of our suppliers, and we closely monitor stock levels to maintain adequate supplies.
In 2025, markets experienced increased pressure because of ongoing geopolitical tensions. QIAGEN's strong material positions and thorough coverage ensure that customer product availability remains unaffected at present. However, uncertainty remains about how markets may develop in 2026 in light of ongoing geopolitical tensions.
U.S. legislation mandates transparency in sourcing conflict minerals-tantalum, tin, tungsten and gold-from mines in the Democratic Republic of Congo (DRC) and its adjoining countries. Some of our instrumentation components, purchased from third-party suppliers, contain gold. As required, we investigate our supply chain and disclose any use of conflict minerals from these regions. Annually, we conduct due diligence to determine the presence and origin of conflict minerals in our products. Since we do not purchase directly from smelters or refineries, we rely on supplier declarations. We filed our latest conflict minerals disclosure with the SEC on Form SD for the year ended December 31, 2024, on May 30, 2025, and will update our disclosures as required.
Our primary production and manufacturing facilities for consumable products are in Germany, the United States, Spain and China. Our software development facilities are in the United States, Germany, Poland, Denmark and
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 32
Romania, and our Center of Excellence for the development of companion diagnostics for personalized healthcare is in the United Kingdom.
Our production and manufacturing operations are highly integrated and supported by sophisticated inventory control and production-planning processes. Production management personnel are highly qualified, and many have advanced degrees in engineering, business and science. In recent years, we have made capital investments principally in automated and interchangeable production equipment to expand production capacity and improve operating efficiency. We have also invested in enterprise systems to support production planning and operational control, including continued deployment and enhancement of SAP-based systems. SAP R/3 is used to integrate the majority of our operating subsidiaries, and we are in the process of a multi-year implementation of S/4HANA.
In addition, capital expenditures include selected investments intended to support energy efficiency and emissions reduction initiatives, including renewable energy projects. Capital expenditures for property, plant and equipment totaled $201.0 million in 2025, $167.2 million in 2024 and
$149.7 million in 2023. These capital expenditures were financed from operating cash flows, and we expect operating cash flows to remain the primary source of funding for future capital expenditures.
We have an established quality system, including standard manufacturing and documentation procedures, intended to ensure that products are produced and tested in accordance with the FDA's Quality System Regulations, which impose current Good Manufacturing Practice (cGMP) requirements. For facilities that accommodate cGMP production, special areas were built, and these facilities operate in accordance with cGMP requirements.
The consumable products manufactured at QIAGEN GmbH in Germany and QIAGEN Sciences LLC in Maryland are produced under ISO 9001: 2015, ISO 13485:2016, MDSAP. By the end of 2025, we aim to complete the implementation of ISO 50001, a voluntary international standard that aids organizations in managing their energy usage. Our certifications form part of our ongoing commitment to provide our customers with high-quality, state-of-the-art sample and assay technologies under our Total Quality Management system.
Our corporate headquarters are located in Venlo, Netherlands. The below table summarizes our largest facilities. Other subsidiaries throughout the world lease smaller amounts of space.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 33
Facility location
Country
Purpose
Owned or leased
Square feet
Hilden
Germany
Manufacturing, warehousing, distribution, research and development and administration
Owned
986,000
Germantown, Maryland
U.S.
Manufacturing, warehousing, distribution and administration
Owned
285,000
Shenzhen
China
Development, manufacturing, warehousing, distribution and administration
Leased
107,200
Manchester
U.K.
Development and Service Solutions
Leased
96,300
Frederick, Maryland
U.S.
Development, Service Solutions, manufacturing, warehousing and distribution
Leased
76,500
Wrocław
Poland
Business service center
Leased
65,100
Beverly, Massachusetts
U.S.
Enzyme manufacturing
Leased
44,000
Barcelona
Spain
Development, manufacturing, warehousing, distribution and administration
Leased
31,900
Manila
Philippines
Business service center
Leased
29,300
Shanghai
China
Service Solutions and administration
Leased
28,400
Gdańsk
Poland
Enzyme manufacturing, development, warehousing and administration
Leased
23,300
Germantown, Maryland
U.S.
Service Solutions and training center
Leased
13,500
Redwood City, California
U.S.
Bioinformatics
Leased
12,700
Gdynia
Poland
Enzyme manufacturing, development and warehousing
Leased
11,200
Our facilities in Hilden, Germany, and Germantown, Maryland, have the capacity to expand in the future by an additional 300,000 square feet each. Our facility in Ann Arbor, Michigan, was closed in 2025, following the decision to discontinue the NeuMoDx portfolio as discussed in Note 6 "Restructuring."
We believe our existing production and distribution facilities can support anticipated production needs for the next 36 months. Our production and manufacturing operations are subject to various federal, state and local laws and regulations, including environmental regulations. We do not believe we have any material issues relating to these laws and regulations.
As a company headquartered in the European Union (EU), we recognize freedom of association and collective bargaining as fundamental to maintaining a positive relationship between management and employee representatives. A significant portion of our workforce is employed in
Organization for Security and Co-operation in Europe (OSCE) member states, and we comply with all applicable labor laws in every region where we operate. Management values its relationships with regional labor unions and employees, and considers them to be positive.
We are committed to respecting and promoting human rights, as outlined in our Human Rights Policy, available on our website at https://www.qiagen.com. This policy is communicated globally via our Company intranet and provided to all new employees. We foster an open-door workplace culture where employees can freely raise concerns with management or Human Resources without fear of retaliation. Our policy explicitly ensures that employees may discuss working conditions openly without risk of reprisal, intimidation or harassment.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 34
The following tables provide information on the number of employees by geographical region and main category of activity as of December 31, 2025, 2024 and 2023:
Employees by region 2025 2024 2023
Americas
1,210
1,252
3,352
1,161
1,329
Europe, Middle East & Africa
3,318
3,453
Asia Pacific, Japan and Rest of World
1,126
1,185
Total
5,654
5,765 5,967
Employees by function 2025 2024 2023
Production
27 %
28 %
18 %
37 %
6 %
11 %
28 %
Research & Development
17 %
18 %
Sales
38 %
37 %
Marketing
6 %
6 %
Administration
12 %
11 %
Total
100 %
100 % 100 %
Depending on local laws and customs, there are different types of employment ranging from long-term fixed contracts to temporary positions, along with flexible time and programs for employees returning to work after parental leave. In 2025, temporary employees with a fixed-term work contract represented 5.8%.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 35
Risks and Risk Management
Role Responsibility
Our Approach
Our risk management approach is built on four key principles:
Active involvement of the Supervisory Board and senior management
Comprehensive policies and procedures
Audit Committee of the Supervisory Board
The Audit Committee of the Supervisory Board oversees the effectiveness of the Company's risk management and internal control systems, regularly reviews and discusses key risks, the overall risk profile, and emerging threats, and evaluates the adequacy of internal controls related to financial reporting, compliance, and operational risks to ensure robust governance and organizational resilience.
Robust risk monitoring, management and information systems
Effective internal controls
Governance and oversight
QIAGEN is managed by a Managing Board and an independent Supervisory
Managing Board The Managing Board provides strategic oversight and governance to ensure that risk management is fully embedded into QIAGEN's long-term objectives and organizational structures, regularly reviewing principal risks, internal controls, and regulatory compliance while overseeing the effectiveness of the risk management system (RMS); it also ensures accurate and transparent external risk disclosures and supports senior management in sustaining a
strong, organization-wide risk culture.
Board, both appointed at the Annual General Meeting of Shareholders. The
Managing Board oversees our risk management system, developing and implementing strategies, controls and mitigation measures to identify and manage current and emerging risks. These risk management policies are embedded in our corporate governance framework, code of ethics and financial reporting controls. Dedicated functional experts continuously evaluate and address business risks.
Executive Committee
Enterprise Risk Management (ERM)
The Executive Committee approves and aligns the ERM and RMS frameworks with QIAGEN's strategic objectives, promotes a strong risk-aware culture, conducts quarterly reviews of key risks and opportunities, ensures effective governance and resources for risk management, and continuously monitors and improves the organization's risk culture.
The Enterprise Risk Management function develops, implements, and continually enhances the ERM framework and processes while coordinating risk management activities across the organization; guides and supports Risk Owners in identifying, assessing, and reporting risks; prepares and delivers risk reports to the Executive Committee and external stakeholders; monitors key risks and opportunities through workshops and assessments; and serves as the primary contact for external audits and regulatory reporting.
Risk Owners Risk Owners identify, assess, and report risks and opportunities within their responsibility, decide and implement appropriate risk response strategies, continuously monitor risk progression and the effectiveness of mitigation measures, escalate risks to the ERM team when they cannot be adequately mitigated, and maintain the risk register by updating entries and providing incident or ad-hoc reports as necessary.
Employees Employees are expected to understand and manage the risks relevant to their roles, follow all established risk management policies and procedures, and actively contribute to a risk-aware culture through their everyday actions and decision-making.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 36
QIAGEN Enterprise Risk Management framework
The risk management framework at QIAGEN is built on the internationally recognized standard ISO 31000, integrating risk management into every aspect of the organization's purpose, governance, strategy and operations. The ERM policy establishes a structured approach for identifying, assessing, and responding to key risks and opportunities that could impact the ability of QIAGEN to achieve its objectives. This framework defines clear roles and responsibilities-spanning the Managing Board, Executive Committee, ERM function, Risk Owners, and the Audit Committee of the Supervisory Board-and sets out principles for risk appetite, tolerance thresholds, and risk profile monitoring. The ERM cycle is continuous and iterative, aligning risk management activities with strategic planning, financial cycles and operational decision-making. Key risks are reviewed at least quarterly, with ad-hoc assessments triggered by significant internal or external events, ensuring that risk management remains dynamic and responsive to change. The policy governing the risk management system (RMS) further details how risk is managed through the Three Lines Model, which delineates accountability across operational management, risk oversight and internal audit. The RMS provides a comprehensive process for risk identification, analysis, evaluation, response and monitoring, supported by tools such as the Risk Universe and Risk Register. Risks are assessed using top-down and bottom-up approaches, with prioritization based on likelihood, impact and alignment with QIAGEN's risk appetite. The framework emphasizes a robust risk culture, transparency, and collaboration, ensuring that risk management is a shared responsibility and embedded in daily business activities. Regular reviews and continuous improvement of the ERM and RMS frameworks ensure that QIAGEN remains resilient, compliant, and well-positioned to capitalize on opportunities while mitigating threats.
Assessment of effectiveness of internal risk management and control systems
The Managing Board assesses the effectiveness of QIAGEN's internal risk management and control systems in relation to operational, compliance and reporting risks on an ongoing basis and at least annually. This assessment is informed by the continuous ERM cycle (including quarterly reviews of key risks
and ad-hoc assessments triggered by significant events), the monitoring performed by Risk Owners and relevant oversight functions and the assurance activities embedded in the Three Lines Model. The outcomes of this monitoring and assurance are reviewed within management governance forums and discussed with the Audit Committee of the Supervisory Board as part of the governance cycle, including the status of remediation actions for identified deficiencies and observations.
Risk classification and assessment
We categorize risks into five main types:
Strategic risk - refers to the potential for losses due to a failed business strategy, planning or decision-making. It is associated with the overall future business plans and strategy of a company, including mergers and acquisitions, management of external network/partnerships or changes in management.
Operational risk - is defined as the risk of loss resulting from inadequate or defective systems and internal processes, from human or technical failure and from damage to physical assets.
Compliance risk - refers to the potential for legal penalties, financial forfeiture, and damage to reputation that a company could face as a result of failing to comply with laws, regulations, industry standards or codes of conduct applicable to its business activities.
Financial risk - refers to the possibility of a company experiencing financial losses due to changes on the financial market or wrong/insufficient financial structure management.
External risk - refers to the potential threats or uncertainties that originate outside of a company's control and can negatively impact its operations, performance, or profitability. These risks arise from the organization's interactions with the natural environment, society and regulatory frameworks, and they can affect the long-term sustainability of the business.
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 37
All risks are assessed based on their likelihood and potential impact on our ability to achieve business objectives. The goal is to identify risks that could materially threaten our success and to implement timely mitigation actions.
Internal controls and compliance
Our corporate governance framework defines the roles of the Managing Board, Supervisory Board and Audit Committee, as detailed under Corporate Governance. We maintain internal controls to ensure the integrity of financial reporting, further described in Controls and Procedures.
Additionally, our Compliance Committee, composed of senior executives from multiple functions, oversees compliance with legal and regulatory requirements and ensures adherence to corporate policies, including our Code of Conduct and Ethics as described in the Corporate Governance section of this annual report.
Risk appetite
Risk appetite is the amount and category of risk that QIAGEN is willing to pursue or retain in the pursuit of its objectives. The risk appetite is documented in a formal statement owned by the Executive Committee, while the Managing Board provides oversight and approval to ensure alignment with the company's strategic direction. This statement serves as a guiding principle for senior management in daily decision-making.
It defines clear parameters for acceptable and unacceptable risks, ensuring consistent and aligned decisions across the organization, and is reviewed and updated annually to remain aligned with strategic priorities.
QIAGEN maintains a balanced risk appetite, seeking to pursue strategic growth opportunities while maintaining robust controls to ensure that risks are managed within defined tolerances and do not compromise our long-term objectives, regulatory compliance or stakeholder trust.
Our business faces significant risks that also threaten the entire industry. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs. In addition, risks and
uncertainties that are currently unknown to QIAGEN or are considered immaterial might affect its business, operations and financial condition. This report also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors including the risks described below and elsewhere in this annual report. The risks described below are grouped into main categories, with the risks within each category listed the significant risks. The risks mentioned reflect our risk assessment but do not imply that the company has no other risks and cannot have a material adverse impact on our results of operations, liquidity, or capital resources.
Summary of risk factors
QIAGEN operates in a complex and evolving global environment that presents a broad range of strategic, operational, financial, compliance and external risks which could, individually or collectively, affect the achievement of its strategic objectives, financial condition or long-term sustainability. We maintain a structured enterprise risk management framework designed to identify, assess, and manage these risks; however, no assurance can be given that all risks can be fully anticipated or mitigated.
Strategic risks arise from the need to continuously align our strategy with rapidly changing market conditions, technological developments and stakeholder expectations. This includes the effective integration of environmental, social and governance considerations into decision-making, the successful development and commercialization of innovative products and the ability to respond to competitive pressures and disruptive technologies. Our broad presence in global markets and the execution and integration of acquisitions may expose us to additional economic, political and regulatory uncertainties, potentially affecting anticipated benefits and growth trajectories.
Operational risks relate to the complexity of the company's global operations and reliance on people, systems, suppliers, and partners. The loss of key personnel, disruptions to manufacturing or supply chains, or insufficient resilience could adversely impact operational performance. Increased reliance on digital platforms, data, and advanced technologies, including artificial
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 38
intelligence, may introduce ethical, security and governance challenges. Cyber security incidents, system outages or failures to adequately protect sensitive information could result in operational disruption, regulatory scrutiny or reputational harm.
Compliance risks stem from operating in a highly regulated environment across multiple jurisdictions. We are subject to evolving legal and regulatory requirements related to product approvals, quality standards, data protection, anti-bribery and anti-corruption laws, intellectual property, environmental regulations and supply-chain due-diligence obligations. Failure to comply with these requirements, or delays in adapting to regulatory changes, could result in fines, litigation, restrictions on market access, or damage to our reputation.
Financial risks include exposure to changes in tax laws and interpretations, global minimum tax regimes, foreign exchange fluctuations and the potential impairment of goodwill and intangible assets. Our capital structure and debt obligations may limit financial flexibility, while future capital requirements may depend on market conditions and access to funding on acceptable terms.
Variability in customer purchasing patterns and reimbursement environments may also affect forecasting accuracy and financial performance.
External risks arise from factors largely beyond the company's control, including global economic uncertainty, inflationary pressures, interest rate movements, geopolitical conflicts, trade restrictions and changes in public funding or reimbursement policies. These factors may influence customer demand, supply-chain stability, cost structures and market access. In addition, evolving stakeholder expectations related to sustainability and corporate responsibility may affect competitiveness, reputation and long-term value creation.
While we actively monitor and manage these risks within our defined risk appetite, the realization of any of these uncertainties could materially and adversely affect our business, financial condition, results of operations or strategic objectives.
Strategic risks
Our presence in potential high-growth markets exposes us to economic, political and regulatory risks.
In markets emerging across the Middle East and Asia, we may face heightened risks compared to regions where we have an established presence. These risks include:
Economic volatility, particularly in markets reliant on a limited range of industries;
Weak legal systems, which may hinder contract enforcement and intellectual property protection;
Government instability, policy changes and privatization efforts that could impact operations;
Foreign exchange controls that may restrict the movement of funds; and
Abrupt changes in customs and tax regulations, affecting product movement and financial performance.
Additionally, conducting business across multiple jurisdictions-such as moving products between countries or providing services from subsidiaries abroad-increases exposure to regulatory shifts and compliance challenges. These factors could negatively impact our operations and financial results.
Emerging competitors and rapid technological advances in diagnostics, combined with regulatory hurdles, threaten the market position, profitability and growth prospects of our diagnostic and syndromic testing products.
The competitive landscape for our diagnostic portfolio, including QuantiFERON, QIAcuity and QIAstat-Dx, is evolving rapidly. Competitors may introduce new technologies, expand strategic partnerships or obtain regulatory approvals earlier than anticipated, which could adversely impact adoption of our products, limit market share expansion or render certain offerings less competitive. For example, announcements by major industry participants regarding advancements in latent tuberculosis testing, as well as new point of care syndromic testing platforms introduced in key markets, illustrate the pace
Management Report
QIAGEN N.V. | Annual Report 2025 Overview Corporate Governance Financial Statements Appendices Page 39
at which competitive dynamics can shift. These developments highlight that the absence of clear current regulatory or clinical progress from competitors does not eliminate the risk of future market disruptions.
Additionally, new instruments and assay systems brought to market by competitors may target both established and emerging market segments, potentially outpacing the capabilities of our current technologies. Competitor expansion into the U.S., Europe, Japan and other regions-coupled with evolving trade policies, including U.S. tariffs-may create pricing pressures, influence customer purchasing behavior or challenge our ability to match product breadth and performance.
Regulatory requirements further contribute to this risk. The need to secure timely approvals for new assays or platform enhancements may delay our product launches, limit our ability to respond to market shifts, or hinder execution of our growth strategies. If we do not meet development timelines or effectively navigate regulatory pathways, we may be unable to achieve anticipated revenue targets or capitalize on market opportunities.
If we fail to keep pace with technological innovation, respond to competitive pressures or obtain required regulatory clearances in a timely manner, our market position could weaken, our profitability could be adversely impacted and our ability to achieve planned growth-particularly in high growth diagnostic segments-could be materially and negatively affected.
Challenges in managing growth and acquisition integration may limit expected benefits and adversely impact our performance.
We have grown significantly in recent years, with total net sales increasing from $1.87 billion in 2020 to $2.09 billion in 2025. This growth has been driven by both organic expansion and strategic acquisitions, including the 2025 acquisitions of Parse Biosciences, Inc. and Genoox. We might continue acquiring businesses that align with our Sample to Insight strategy in molecular research and clinical testing. However, successful integration of acquisitions requires significant resources, coordination and expense.
Our ability to manage ongoing growth and execute on expansion initiatives is subject to risks, and the outcomes may not achieve the anticipated benefits or
align with evolving operational, financial or strategic expectations. As we continue to broaden our activities and pursue opportunities to strengthen our portfolio-including through the acquisition of complementary businesses-we may be required to adapt our internal processes, systems and organizational structures to support a larger and more complex operating model. These efforts may place increasing demands on management attention and require significant capital and human resources.
The successful integration of acquired businesses, technologies and personnel remains inherently uncertain. Expansion activities may expose us to challenges related to aligning operations, maintaining consistent standards, integrating systems and processes, and retaining key talent. Acquisitions can also introduce additional regulatory, commercial and financial considerations, including potential liabilities, shifting market dynamics or delays in realizing intended synergies. Performance may also depend on external parties, such as suppliers, partners or acquired teams, whose activities we do not fully control.
As we grow, we may need to expand or enhance our operational and financial control frameworks to ensure continued reliability, consistency and compliance across a broader footprint. In some cases, implementation of new systems or scaling of existing capabilities may temporarily disrupt operations or increase costs. Divergent stakeholder expectations regarding the pace and direction of expansion may also lead to reputational risks if outcomes are perceived as insufficient or misaligned.
Failure to effectively manage growth or integrate acquisitions could result in operational inefficiencies, delays in execution, increased expenses, or challenges in maintaining expected performance levels. In certain circumstances, these developments may also affect our financial condition, reputation or ability to achieve long-term strategic objectives.
We rely on collaborative commercial relationships to develop and/or market some of our products.
We rely on a variety of external partners to develop, commercialize, and distribute certain products. These collaborations-whether with academic institutions, pharmaceutical and biotechnology companies, or regional
Disclaimer
Qiagen NV published this content on May 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 12, 2026 at 08:57 UTC.